Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry

San Diego, CA, January 6, 2026 — Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript detailing the discovery and optimization of VVD-214, the company’s covalent inhibitor of Werner helicase (WRN), on the cover of the Journal of Medicinal […] The post Vividion Publishes Discovery of WRN Inhibitor VVD-214 in Journal of Medicinal Chemistry appeared first on Vividion Therapeutics .